StockData
Silence Therapeutics plc logo

Silence Therapeutics plc (SLN) stock

SLNNasdaqPharmaceutical PreparationsAlso trades as SLNCF
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 13, 2026Score 7/30
$19.80+0.00 (0.00%)

Close on Nov 17, 2026Market cap $935.48MP/E –Yield –

Silence Therapeutics price to book ratio

The price-to-book ratio is market cap divided by shareholders' equity.

Silence Therapeutics's price to book ratio was 24.3× on Nov 11, 2026, against 4.3× a year earlier. Over the last 5 years it ranged from 1.0× to 45.9×, with a median of 13.4×.

Price to Book Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 202624.3×+20.4
2025Dec 31, 20253.9×−8.5
2024Dec 31, 202412.4×−10.5
2023Dec 29, 202322.9×−13.6
2022Dec 30, 202236.5×–

More Silence Therapeutics figures

See a number that looks wrong?